President Trump left Walter Reed National Military Medical Center on Monday evening after spending three days there receiving treatment for the novel coronavirus.
Trump walked out of the hospital just after 6:30 p.m., ignoring questions from reporters while offering a wave and saying, “thank you very much, everybody.” He now returns to the White House where he will continue to be treated for COVID-19.
Ridgewood NJ, jobs , jobs, jobs in the last jobs report before the November election released Friday, September’s very positive jobs numbers actually confirm that we may be experiencing the most dynamic economic recovery in American history.
In September the US Economy added 661,000 jobs despite some of the best efforts by Governor Murphy and Governor Cuomo and tyrannical lock downs.
New Brunswick NJ, according to Johns Hopkins Center for Health Security , Johnson & Johnson (J&J) published (preprint) preliminary findings from the Phase 1/2a clinical trials for its candidate SARS-CoV-2 vaccine (Ad26.COV.S). The studies included nearly 800 participants, who were split into 3 cohorts for the randomized, double-blinded, placebo-controlled study. The first 2 cohorts were made up of 402 healthy adults aged 18-55 years, and the third cohort included 394 healthy adults over the age of 65. The vaccine was given as a single dose or 2 doses administered 56 days apart. The vaccine was generally well tolerated, and the researchers reported 2 serious adverse events. One of the serious adverse events was determined to be unrelated to the vaccine, and the other was a fever that resolved within 12 hours.
Ridgewood NJ, Governor Phil Murphy held Facebook Live chat with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases Thursday morning.
That look of Rut-Ro when Dr. Fauci tells you during a live TV show that it’s becoming scientifically safe for your State to reopen.
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminently. Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.
Ridgewood NJ, according to Johns Hopkins Center for Health Security as governments and countries press ahead with efforts to develop their own SARS-CoV-2 vaccine—as opposed to large, collaborative, multilateral efforts—”vaccine nationalism” not only creates challenges for the equitable global availability of a future vaccine, it also provides incentive for increased foreign intrusion and “espionage targeting vaccine research and development.” According to analysis published by the Council on Foreign Relations, espionage (including cyber espionage) is not technically prohibited under international law; however, it would violate international law if it were to result in “significant adverse or harmful consequences.” The analysis highlights the “ubiquity of cyber espionage” on SAR-CoV-2 vaccine efforts and the difficulty in “defending against or deterring” it.
People have been laid off from their jobs because of COVID-19 recently. Finding a job these days is a bit challenging. We’re going through a new situation, and we’re gradually adapting to it. Part of adapting is finding new jobs online. It took a pandemic to teach us that we can do most, if not all, types of work from home. The problem lies in the hiring process. How can the recruiters and employers trust us when they’ve only seen us online? Here are our tips on how to make yourself credible when applying for an online job.
Oxford UK, according to Johns Hopkins Center for Health Security, less than a week after suspending Phase 3 clinical trials for its candidate SARS-CoV-2 vaccine due to a serious adverse event, AstraZeneca announced that the trials have resumed in the UK. According to a press release issued by AstraZeneca, the trials resumed after the UK government’s Medicines Health Regulatory Authority (MHRA) evaluated the evidence and determined that it was safe to continue testing the vaccine. The press release states that AstraZeneca and the University of Oxford are not permitted to “disclose further medical information” regarding the adverse event, presumably including the associated safety data reviewed by MHRA or the results of their analysis. It appears that the Phase 3 trials in other countries remain on hold.
Oxford UK, The Phase 3 clinical trial for AstraZeneca’s candidate SARS-CoV-2 vaccine (developed in collaboration with Oxford University) has been paused following the identification of a serious adverse event in one of the participants. Neither AstraZeneca nor Oxford University have yet disclosed details of the adverse event, which reportedly occurred in the UK; however, The New York Times reports that the patient developed transverse myelitis. It has not yet been determined whether the condition was associated with the vaccine. An earlier clinical trial for the AstraZeneca vaccine was also paused following the diagnosis of transverse myelitis in a participant, but the trial resumed after a safety review determined that the condition was not related to the vaccine.
Ridgewood NJ, AstraZeneca COVID19 vaccine expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and led by AstraZeneca. The NIAID-supported COVID-19 Prevention Network (CoVPN) will participate in the trial.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine. Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible.”
River Vale NJ, Assemblywomen Holly Schepisi comments on the COVID pandemic and the governments response :
“I have struggled on how to properly phrase my thoughts on what has been transpiring over the past six months. There is no eloquent way to phrase what I am about to say so here it goes. The political element underscoring this virus is beyond absurd and the manipulation of people by both political parties is frankly disgusting.
In March a virus hit New Jersey and New York that overwhelmed our hospital systems. No one knew how to treat it and it was obvious that even our medical professionals had no idea initially of what to do. We didn’t know if it was going to impact the healthy, the young, the elderly or all of the above. We didn’t know if masks worked or didn’t. We didn’t know if our loved ones would die if they contracted it. We didn’t know how it spread or once it did what the impact on everyone in society would be. We didn’t know the fatality rates, the infection rates or anything else for that matter.”
Ridgewood NJ, the Centers for Disease Control released information showing how many people who died from COVID-19 had underlying medical conditions that attributed to their death.
According to the report, only 6 percent of deaths have COVID-19 as the only cause mentioned, revealing that 94 percent of patients who died from coronavirus also had underlying health conditions.
President Trump announced Sunday that the Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for convalescent plasma for emergency use to treat patients sickened by the novel coronavirus as a therapeutic.
Trump, who has been looking to announce progress in fighting the virus, touted the news as a “historic breakthrough” against the “Chine virus” at a White House news conference on Sunday, saying it would “dramatically expand access to this treatment.Not resisting further temptation the President hoped the press had a great time at their convention.
Ridgewood NJ, On August 3, 2020, CDC updated its isolation guidance based on the latest science about COVID-19 showing that people can continue to test positive for up to 3 months after diagnosis and not be infectious to others. Contrary to media reporting today, this science does not imply a person is immune to reinfection with SARS-CoV-2, the virus that causes COVID-19, in the 3 months following infection. The latest data simply suggests that retesting someone in the 3 months following initial infection is not necessary unless that person is exhibiting the symptoms of COVID-19 and the symptoms cannot be associated with another illness.
